Yes. In postmenopausal women, estrogen deficiency affects bone cells survival as well as impairs their response to mechanical stimuli and repair of aging bone. Raloxifene acts as an estrogen agonist and represses bone remodeling to the premenopausal range, conserving the function of the bone cells. Thus, bone resorption and degradation are prevented.